or Try an Advanced Search...

    Technical Analysis for JANX - Janux Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 41.72 -0.41% -0.17
    JANX closed down 0.41 percent on Monday, July 1, 2024, on 72 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical JANX trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    MACD Bullish Signal Line Cross Bullish -0.41%
    Pocket Pivot Bullish Swing Setup -0.41%
    Volume Surge Other -0.41%
    NR7 Range Contraction -0.41%
    Wide Bands Range Expansion -0.41%
    Earnings Movers Other 3.42%
    Multiple of Ten Bullish Other 3.42%
    Older End-of-Day Signals for JANX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 8 hours ago
    Down 1% about 8 hours ago
    20 DMA Resistance about 9 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    Up 2% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    JANX Chart by TradingView
    Basic chart:

    Profile

    Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation

    Is JANX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 26 Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy
    Jun 14 TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors
    May 9 We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate
    May 8 Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates
    May 7 Janux Therapeutics GAAP EPS of -$0.30 beats by $0.03
    May 7 Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
    May 2 Janux Therapeutics gains amid renewed takeover speculation
    Apr 30 Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
    Apr 29 Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal
    Apr 17 Take the Money and Run: 3 Overbought Stocks to Sell ASAP
    See more JANX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 65.6
    52 Week Low 5.65
    Average Volume 883,753
    200-Day Moving Average 24.96
    50-Day Moving Average 47.88
    20-Day Moving Average 42.99
    10-Day Moving Average 41.02
    Average True Range 2.75
    RSI (14) 44.75
    ADX 12.29
    +DI 22.77
    -DI 22.59
    Chandelier Exit (Long, 3 ATRs) 47.77
    Chandelier Exit (Short, 3 ATRs) 47.24
    Upper Bollinger Bands 49.94
    Lower Bollinger Band 36.04
    Percent B (%b) 0.41
    BandWidth 32.34
    MACD Line -1.75
    MACD Signal Line -1.87
    MACD Histogram 0.1232
    Fundamentals Value
    Market Cap 1.93 Billion
    Num Shares 46.2 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -28.38
    Price-to-Sales 51.42
    Price-to-Book 1.22
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 44.45
    Resistance 3 (R3) 44.58 43.80 44.00
    Resistance 2 (R2) 43.80 43.10 43.74 43.84
    Resistance 1 (R1) 42.76 42.68 43.28 42.63 43.69
    Pivot Point 41.98 41.98 42.24 41.92 41.98
    Support 1 (S1) 40.94 41.28 41.46 40.81 39.75
    Support 2 (S2) 40.16 40.86 40.10 39.60
    Support 3 (S3) 39.12 40.16 39.45
    Support 4 (S4) 38.99